Solventum Corporation (SOLV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Solventum Corporation (SOLV) trades at $78.27 with AI Score 54/100 (Grade B). Solventum Corporation operates in the healthcare sector, providing a range of medical and dental solutions. Market cap: $13.55B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026SOLV stock analysis for 2026: Analysts have set a consensus price target of $98.50 for Solventum Corporation, suggesting 25.8% upside from the current price of $78.27. The AI MoonshotScore is 54/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SOLV: 4/8 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Solventum Corporation (SOLV) Healthcare & Pipeline Overview
Solventum Corporation, a healthcare solutions provider, develops and commercializes medical and dental products across four segments including Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. With a $13.55B market cap and a 17.3% profit margin, Solventum addresses critical patient needs within the evolving healthcare landscape.
What Is the Investment Thesis for SOLV?
Solventum Corporation presents a notable research candidate within the healthcare sector, driven by its diverse portfolio of medical and dental solutions. With a market capitalization of $13.55B and a P/E ratio of 9.7, the company demonstrates solid financial metrics. A gross margin of 53.7% and a profit margin of 17.3% indicate efficient operations. Growth catalysts include expansion within its Medsurg and Dental Solutions segments, as well as potential advancements in its Health Information Systems. Potential risks include competitive pressures and regulatory changes within the healthcare industry. The company's beta of 0.77 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
SOLV Key Highlights
- Market Cap of $13.55B indicates a strong market presence within the healthcare sector.
- P/E ratio of 9.7 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 17.3% demonstrates efficient profitability in its operations.
- Gross Margin of 53.7% indicates a strong ability to manage production costs.
- Beta of 0.77 suggests lower volatility compared to the overall market, potentially offering a more stable investment.
Who Are SOLV's Competitors?
SOLV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALGN Align Technology, Inc. | $184.52 | +1.67% | $13.21B | 88 |
| RDY Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products and active pharmaceutical ingredients globally. The company | $14.38 | +2.79% | $11.97B | 51 |
| EHC Encompass Health Corporation | $106.46 | +5.00% | $10.56B | 87 |
| ENSG The Ensign Group, Inc. | $168.22 | +2.06% | $9.83B | 77 |
| ELAN Elanco Animal Health Incorporated | $25.00 | +3.78% | $12.49B | 33 |
| HWAIF Healwell AI Inc. | $0.55 | +5.07% | $166.74M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOLV's Key Strengths?
- Diverse product portfolio across multiple healthcare segments.
- Strong brand reputation and established customer relationships.
- Proprietary technologies and intellectual property.
- Efficient operations with a profit margin of 17.3%.
What Are SOLV's Weaknesses?
- Dependence on specific product lines for revenue.
- Potential for product recalls or safety concerns.
- Exposure to regulatory changes in the healthcare industry.
- Limited presence in emerging markets compared to larger competitors.
What Could Drive SOLV Stock Higher?
- Launch of new advanced wound care products in Q3 2026, expected to drive revenue growth in the Medsurg segment.
- Expansion of the Dental Solutions segment into emerging markets, particularly in Asia-Pacific, to capture new growth opportunities.
- Continued investment in R&D to develop innovative health information systems solutions, enhancing the company's competitive advantage.
- Potential acquisitions of complementary businesses to expand the product portfolio and enter new markets by the end of 2026.
What Are the Key Risks for SOLV?
- Intense competition from established healthcare companies, which could lead to pricing pressures and reduced market share.
- Regulatory changes in the healthcare industry, which could impact the company's operations and profitability.
- Patent expirations and generic competition, which could erode revenue from key products.
- Economic downturns affecting healthcare spending, which could reduce demand for the company's products and services.
- Product recalls or safety concerns, which could damage the company's reputation and lead to financial losses.
What Are the Growth Opportunities for SOLV?
- Growth opportunity 1: Expansion in Advanced Wound Care: Solventum can capitalize on the growing market for advanced wound care products, driven by an aging population and increasing prevalence of chronic diseases such as diabetes. The global advanced wound care market is projected to reach $22 billion by 2027. Solventum's Medsurg segment is well-positioned to capture a larger share of this market through innovative product development and strategic partnerships. This expansion can be achieved through increased R&D spending and targeted marketing efforts.
- Growth opportunity 2: Penetration of the Dental Solutions Market: The global dental solutions market is experiencing steady growth, driven by increasing awareness of oral hygiene and advancements in dental technology. Solventum's Dental Solutions segment can expand its market share by introducing new and improved dental and orthodontic products, particularly in emerging markets. The global dental market is expected to reach $40 billion by 2025, offering significant growth opportunities for Solventum.
- Growth opportunity 3: Innovation in Health Information Systems: The demand for advanced health information systems is increasing as healthcare providers seek to improve efficiency, reduce costs, and enhance patient care. Solventum's Health Information Systems segment can drive growth by developing innovative software solutions that leverage artificial intelligence, machine learning, and data analytics. The global healthcare IT market is projected to reach $390 billion by 2027, presenting a substantial growth opportunity for Solventum.
- Growth opportunity 4: Expansion in Purification and Filtration Technologies: The global market for purification and filtration technologies is growing, driven by increasing demand for clean water and air, as well as stringent environmental regulations. Solventum's Purification and Filtration segment can expand its market presence by developing and commercializing advanced filtration solutions for various applications, including healthcare, industrial, and residential. The global filtration market is expected to reach $100 billion by 2026.
- Growth opportunity 5: Strategic Acquisitions and Partnerships: Solventum can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. By acquiring complementary businesses and forming alliances with other healthcare companies, Solventum can accelerate its growth and strengthen its competitive position. This strategy can be particularly effective in expanding its presence in high-growth areas such as digital health and personalized medicine. The timeline for realizing these benefits will depend on the specific acquisitions and partnerships pursued.
What Opportunities Does SOLV Have?
- Expansion into new therapeutic areas and geographic markets.
- Development of innovative products and solutions through R&D.
- Strategic acquisitions and partnerships to expand market share.
- Growing demand for healthcare solutions driven by an aging population.
What Threats Does SOLV Face?
- Intense competition from established healthcare companies.
- Pricing pressures from healthcare providers and payers.
- Patent expirations and generic competition.
- Economic downturns affecting healthcare spending.
What Are SOLV's Competitive Advantages?
- Diversified product portfolio across multiple healthcare segments.
- Established brand reputation and customer relationships.
- Proprietary technologies and intellectual property.
- Strong distribution network and global reach.
What Does SOLV Do?
Solventum Corporation, incorporated in 2023 and based in Saint Paul, Minnesota, is a healthcare company focused on developing, manufacturing, and commercializing a diverse portfolio of healthcare solutions. The company operates through four key segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions such as advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems segment delivers software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The Purification and Filtration segment offers purification and filtration technologies, including filters, purifiers, cartridges, and membranes. Solventum's products are designed to address critical customer and patient needs across the healthcare spectrum, positioning it as a key player in the medical and dental solutions market.
What Products and Services Does SOLV Offer?
- Develops and manufactures medical and dental solutions.
- Offers advanced wound care products and I.V. site management solutions.
- Provides dental and orthodontic products including brackets and aligners.
- Delivers health information systems software for physician documentation and coding automation.
- Offers purification and filtration technologies for various applications.
- Commercializes its products to address critical customer and patient needs in healthcare.
How Does SOLV Make Money?
- Develops and manufactures a range of healthcare products and solutions.
- Sells its products through direct sales, distributors, and partnerships.
- Generates revenue from the sale of medical and dental products, software solutions, and filtration technologies.
- Invests in research and development to innovate and expand its product portfolio.
What Industry Does SOLV Operate In?
Solventum Corporation operates within the healthcare industry, specifically in the medical and dental solutions market. The industry is characterized by continuous innovation, increasing demand for advanced medical technologies, and evolving regulatory landscapes. The competitive landscape includes companies such as ALGN: Align Technology, Inc. and RDY: Dr. Reddy's Laboratories Limited. Solventum's diversified portfolio across Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration positions it to capitalize on various growth opportunities within the broader healthcare market. The global medical devices market is projected to reach $600 billion by 2028, reflecting substantial growth potential.
Who Are SOLV's Key Customers?
- Hospitals and healthcare providers
- Dental clinics and orthodontists
- Healthcare IT departments
- Industrial and commercial businesses requiring filtration solutions
Company Profile
Solventum Corporation operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Maplewood, US. The company is led by CEO Bryan C. Hanson. SOLV has traded publicly since 2024.
Solventum Corporation Financial Trajectory
Solventum Corporation (SOLV) reported $2.01B in revenue for Q1 2026, reflecting 0.5% growth compared to the prior quarter. The company recorded net income of $13.0M, with diluted EPS of $0.07. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SOLV averaged $2.04 in diluted EPS.
How Solventum Corporation Is Valued
Solventum Corporation carries a market capitalization of $13.55B, placing it in the large-cap category. Relative to its peer group, SOLV's quantitative score of 54/100 is below the peer average of 67/100.
ROE 31%Key Financial Metrics
Return on equity for Solventum Corporation stands at 30.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.2%, showing how much profit it generates from its asset base. SOLV trades at a trailing price-to-earnings ratio of 9.67, below the Healthcare sector average of ~23x. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Solventum Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.14 places it in the grey zone, a middle ground that warrants monitoring.
8/8 beatsEarnings Track Record
Solventum Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.4% above estimates on average.
FY2026 estForward Outlook
Wall Street analysts project Solventum Corporation revenue of about $8.19B for fiscal 2026, with EPS near $6.54. The estimate reflects 10 contributing analysts.
Net buyingInsider Activity
Over the past six months, Solventum Corporation insiders filed 15 SEC Form 4 transactions — 2 sales and 13 purchases. On net that is roughly 46K shares acquired (about $124K) — insiders putting money in tends to read as conviction.
SOLV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Solventum's future, indicating that executives believe the company is undervalued.
- Community sentiment has turned positive as discussions around Solventum's innovative solutions gain traction, reflecting growing interest.
- Analysts highlight Solventum's recent partnerships that may enhance its market position and drive revenue growth.
- The company’s focus on sustainability aligns with increasing market demand for eco-friendly solutions, positioning it favorably for long-term growth.
Bear Case
- Some community members express concerns over Solventum's ability to scale operations effectively, which could hinder growth potential.
- Recent news highlights regulatory challenges in the industry, raising uncertainty about Solventum's operational environment.
- Market perception remains cautious due to potential competition from larger players, which might overshadow Solventum's offerings.
- There are mixed reviews on the effectiveness of Solventum's recent product launches, suggesting that market acceptance may be slower than anticipated.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
From the Earnings Call
“We estimate over $100 million of sales timing benefit in Q2 that we expect will reverse in 2026, mostly in Q3.”
— Wayde McMillan, CFO
“As a reminder, our Transform for the Future program is a multiyear $500 million savings program. It is our way of proactively reshaping our operating structure while freeing up resources to invest for the long term.”
— Bryan Hanson, CEO
SOLV Q1 FY2026 earnings call transcript · 2026-05-05
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.01B | $13M | $0.07 |
| Q4 2025 | $2.00B | $63M | $0.36 |
| Q3 2025 | $2.10B | $1.27B | $7.22 |
| Q2 2025 | $2.16B | $90M | $0.51 |
Based on FMP financials and quantitative analysis
SOLV Latest News
-
3 Mid-Cap Stocks We Steer Clear Of
Yahoo! Finance: SOLV News · Jun 29, 2026
-
SOLV Energy: The Pullback Makes The Buy Case Stronger
seekingalpha.com · Jun 25, 2026
-
3 Healthcare Stocks with Questionable Fundamentals
Yahoo! Finance: SOLV News · Jun 25, 2026
-
Why Solventum (SOLV) is a Top Stock for the Long-Term
zacks.com · Jun 25, 2026
SOLV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SOLV.
Price Targets
Consensus target: $98.50
SOLV MoonshotScore
What does this score mean?
The MoonshotScore rates SOLV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
3 Mid-Cap Stocks We Steer Clear Of
SOLV Energy: The Pullback Makes The Buy Case Stronger
3 Healthcare Stocks with Questionable Fundamentals
Why Solventum (SOLV) is a Top Stock for the Long-Term
Leadership: Bryan C. Hanson
CEO
Bryan C. Hanson serves as the CEO of Solventum Corporation, bringing extensive leadership experience in the healthcare industry. Prior to this role, Hanson held various executive positions at leading medical technology companies. His career spans over two decades, with a focus on driving innovation, improving operational efficiency, and expanding market presence. Hanson holds advanced degrees in engineering and business administration, providing a strong foundation for strategic decision-making and organizational leadership. He is known for his commitment to fostering a culture of collaboration and innovation within the organizations he leads.
Track Record: Under Bryan C. Hanson's leadership, Solventum Corporation has focused on strengthening its core business segments and expanding into new growth areas. Key achievements include the successful launch of several innovative products and the implementation of strategic initiatives to improve operational efficiency. Hanson has also prioritized building strong relationships with key customers and partners, contributing to the company's continued success and market leadership. His strategic vision has been instrumental in positioning Solventum for long-term growth and value creation.
Common Questions About SOLV (Healthcare)
What does Solventum Corporation do?
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes a range of medical and dental solutions. The company operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Its products include advanced wound care, dental aligners, healthcare software, and filtration technologies. Solventum aims to address critical customer and patient needs across the healthcare spectrum, positioning itself as a key player in the medical and dental solutions market.
What do analysts say about SOLV stock?
Analyst consensus on Solventum Corporation (SOLV) stock is currently neutral, reflecting the company's solid financial metrics and growth potential balanced against industry-specific risks. Key valuation metrics include a P/E ratio of 9.7 and a profit margin of 17.3%. Growth considerations center on the company's ability to expand its market share in key segments and innovate new products. Analysts highlight the company's diversified portfolio and established brand reputation as positive factors, while noting potential challenges from competition and regulatory changes. No buy or sell recommendations are made.
What are the main risks for SOLV?
The main risks for Solventum Corporation include intense competition from established healthcare companies, which could lead to pricing pressures and reduced market share. Regulatory changes in the healthcare industry could also impact the company's operations and profitability. Additionally, patent expirations and generic competition could erode revenue from key products. Economic downturns affecting healthcare spending and potential product recalls or safety concerns also pose significant risks to the company's financial performance and reputation.
What are the key growth opportunities for SOLV in healthcare?
Solventum Corporation has several key growth opportunities in the healthcare sector. These include expanding its presence in the advanced wound care market, penetrating the dental solutions market with innovative products, and developing advanced health information systems that leverage AI and data analytics. Additionally, strategic acquisitions and partnerships can help Solventum expand its product portfolio and enter new markets. These opportunities will allow Solventum to capitalize on the increasing demand for healthcare solutions and drive long-term growth.
How does Solventum Corporation manage patent expiration risks?
Solventum Corporation manages patent expiration risks through a combination of strategies, including continuous innovation, lifecycle management, and strategic partnerships. The company invests heavily in research and development to create new and improved products that are protected by patents. Lifecycle management strategies involve extending the market exclusivity of existing products through new formulations, delivery systems, or indications. Strategic partnerships with other companies can also help Solventum mitigate patent expiration risks by diversifying its product portfolio and accessing new technologies.
What are the key factors to evaluate for SOLV?
Solventum Corporation (SOLV) holds an AI score of 54/100 (moderate). P/E: 9.7x vs the S&P 500's ~20-25x. Analysts target $98.50 (+26%). Not financial advice.
How frequently does SOLV data refresh on this page?
SOLV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SOLV's recent stock price performance?
Solventum Corporation (SOLV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple healthcare segments. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided data and may not reflect real-time market conditions.
- Financial metrics are as of the latest available data and are subject to change.